IVF

INVO Bioscience, Inc. (INVO) - 10-Q Summary

Business Context and Reporting Period

Company: INVO Bioscience, Inc. (formerly Emy's Salsa Aji Distribution Company, Inc.)
Reporting Period: Quarter and nine months ended September 30, 2009
Business Stage: Development stage company focused on the INVOcell device, an assisted reproductive technology alternative to IVF.
Operations: The company holds CE Marking for the European Economic Area and is pursuing FDA 510(k) clearance for the U.S. market. Revenue is currently derived from international sales to distributors and physicians.

Key Financial Metrics

Note: The company reported a negative gross margin of $(830) for the quarter due to low volume sales and high shipping costs relative to revenue.

Material Changes vs. Prior Period

• Revenue: Increased from $0 in the prior year periods to $2,852 (quarter) and $56,298 (nine months) due to initial international shipments.
• Net Loss: Significantly increased to $(3.4M) for the quarter and $(4.5M) for the nine months. This is primarily driven by non-cash expenses related to the fair value adjustment of derivative liabilities and amortization of debt discounts.
• Derivative Liabilities: A new liability of $3,593,414 was recorded due to the adoption of ASC 815-40 regarding convertible notes and warrants issued in the quarter. This resulted in a $380,036 expense for the change in fair value and a $2.56M charge to operations for the initial valuation.
• Debt: Issued $545,000 in convertible "Bridge Notes" during the quarter. Related party notes payable increased to $158,462.
• Operating Expenses: Selling, general, and administrative (SG&A) expenses decreased slightly for the quarter ($293,588 vs $365,121) due to reduced travel, but increased significantly for the nine-month period ($1.39M vs $660,875) due to expanded staffing and public company compliance costs.

Outlook, Risks, and Contingencies

• Going Concern: The filing explicitly states substantial doubt about the company's ability to continue as a going concern. The company has a cumulative net loss of $6.59M since inception and requires approximately $175,000 per month to fund operations.
• Financing: On October 28, 2009 (subsequent event), the company entered into a Reserve Equity Financing (REF) agreement with AGS Capital Group, LLC, allowing for up to $10,000,000 in funding over two years. The company intends to limit initial issuance to approximately 8.1M shares.
• Regulatory: While CE Marked for Europe, the company faces delays in local country registrations and is awaiting FDA 510(k) clearance for the U.S., expected potentially by end of 2010 pending clinical trials.
• Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of September 30, 2009, citing a material weakness in internal control over financial reporting that has not been remediated.
• Anti-Dilution: The issuance of convertible notes at $0.10/share triggered anti-dilution clauses for previous investors, resulting in the issuance of 1.125M shares and the forfeiture of 562,500 shares by a major shareholder (Lionshare Ventures).

Investor Verification Checklist

• Cash Runway: Verify if the $194,405 cash balance is sufficient to cover the stated $175,000 monthly burn rate without immediate drawdown on the AGS REF agreement.
• Derivative Liability Valuation: Review the Black-Scholes assumptions (volatility of 275-309%) used to calculate the $3.6M derivative liability, as this significantly impacts the reported net loss.
• Debt Covenants: Confirm the terms of the $545,000 Bridge Notes and related party loans, specifically regarding conversion triggers and maturity dates.
• Revenue Sustainability: Assess the scalability of revenue given the current negative gross margin and reliance on small, high-cost international shipments.
• Internal Controls: Evaluate the timeline and plan for remediating the material weakness in internal controls over financial reporting.